a novel drug for prevention and treatment peripheral neuropathy symptoms

Informations projet

MP-101

N° de convention de subvention: 854931

DOI

10.3030/854931

Projet clôturé

Date de signature de la CE 31 Janvier 2019

Date de début 1 Janvier 2019

Date de fin 30 Avril 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

METYS PHARMACEUTICALS AG
Switzerland

Periodic Reporting for period 1 - MP-101 (a novel drug for prevention and treatment peripheral neuropathy symptoms)

Période du rapport: 2019-01-01 au 2019-04-30

Résumé du contexte et des objectifs généraux du projet

There were over 18 million new cases of cancer worldwide in 2018, out of which about 3.7 million were in Europe. Up to 40% of all cancer patients develop chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a condition that affects the peripheral nervous system, leading to long-lasting, painful, and difficult-to-treat symptoms. At present, only a few therapies are available for the treatment of peripheral neuropathy with moderately effectiveness, but none is specifically developed for CIPN and with substantial side effects for patients. Metys Pharmaceuticals Ltd. has developed MP-101 - a novel, non-sedating, painkiller for prevention and for treatment of CIPN-associated neuropathic pain.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

From 1 January until 30 April 2019, Metys Pharmaceuticals Ltd. used Phase 1 funding to carry out an extensive study with the objective to identify the technical and business requirements of delivering a finished and legally approved commercial version of MP-101. From a technical point of view, Metys reviewed in detail the current stage of MP-101 and defined a sound development plan for its approval and commercialisation. From a business point of view, the Company performed a deep market analysis, verified its business model and established a sound go-to-market strategy.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Metys’ novel drug aims at a clinical application in response to yet unanswered medical needs of cancer chemotherapy-induced peripheral neuropathy symptoms. So far, in fact there has been very limited progress in discovery of agents that show benefit in the treatment of CIPN. MP-101 has potential to become the first drug approved for the prevention and management of CIPN.

peripheral neutopathy